Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Feb 19;372(8):711-23.
doi: 10.1056/NEJMoa1405044.

A 9-valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women

Collaborators, Affiliations
Free article
Clinical Trial

A 9-valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women

Elmar A Joura et al. N Engl J Med. .
Free article

Abstract

Background: The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age.

Methods: We performed a randomized, international, double-blind, phase 2b-3 study of the 9vHPV vaccine in 14,215 women. Participants received the 9vHPV vaccine or the qHPV vaccine in a series of three intramuscular injections on day 1 and at months 2 and 6. Serum was collected for analysis of antibody responses. Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Papanicolaou testing) was performed regularly. Tissue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical excision procedure and conization) was tested for HPV.

Results: The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e., disease caused by HPV types included in the 9vHPV vaccine and those not included) in the modified intention-to-treat population (which included participants with and those without prevalent infection or disease) was 14.0 per 1000 person-years in both vaccine groups. The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52, and 58 in a prespecified per-protocol efficacy population (susceptible population) was 0.1 per 1000 person-years in the 9vHPV group and 1.6 per 1000 person-years in the qHPV group (efficacy of the 9vHPV vaccine, 96.7%; 95% confidence interval, 80.9 to 99.8). Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine. Adverse events related to injection site were more common in the 9vHPV group than in the qHPV group.

Conclusions: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine. The 9vHPV vaccine did not prevent infection and disease related to HPV types beyond the nine types covered by the vaccine. (Funded by Merck; ClinicalTrials.gov number, NCT00543543).

Comment in

  • HPV "coverage".
    Schuchat A. Schuchat A. N Engl J Med. 2015 Feb 19;372(8):775-6. doi: 10.1056/NEJMe1415742. N Engl J Med. 2015. PMID: 25693018 Free PMC article. No abstract available.
  • A 9-Valent HPV Vaccine in Women.
    Joura E, Bautista O, Luxembourg A. Joura E, et al. N Engl J Med. 2015 Jun 25;372(26):2568-9. doi: 10.1056/NEJMc1504359. N Engl J Med. 2015. PMID: 26107058 No abstract available.
  • A 9-Valent HPV Vaccine in Women.
    Wieland U, Brockmeyer NH, Kreuter A. Wieland U, et al. N Engl J Med. 2015 Jun 25;372(26):2566. doi: 10.1056/NEJMc1504359. N Engl J Med. 2015. PMID: 26107059 No abstract available.
  • A 9-Valent HPV Vaccine in Women.
    Tempfer C. Tempfer C. N Engl J Med. 2015 Jun 25;372(26):2566-7. doi: 10.1056/NEJMc1504359. N Engl J Med. 2015. PMID: 26107060 No abstract available.
  • A 9-Valent HPV Vaccine in Women.
    Mihalyi A, Ryser M, Struyf F. Mihalyi A, et al. N Engl J Med. 2015 Jun 25;372(26):2567. doi: 10.1056/NEJMc1504359. N Engl J Med. 2015. PMID: 26107061 No abstract available.

Similar articles

See all similar articles

Cited by 305 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback